In vitro chemoresistance testing in well-differentiated carcinoid tumors

Annals of Surgical Oncology
John M LyonsEugene A Woltering

Abstract

Well-differentiated, "typical" carcinoid tumors traditionally have a very poor response to chemotherapy. We hypothesized that tumor specimens from well-differentiated carcinoid tumors would be highly resistant to the effects of chemotherapy when tested against a variety of antineoplastic agents in vitro. Ninety-eight typical carcinoid specimens were surgically harvested, cultured, and tested against antineoplastics in vitro. (3)H-Thymidine incorporation was used to assess the percentage of cell-growth inhibition (PCI) of tested specimens. PCI was used to determine if specimens had extreme drug resistance (EDR), intermediate drug resistance (IDR), or low drug resistance (LDR) to each reagent against which they were tested. Seventy specimens generated results. Each was tested with an average of six drugs. The mean proportions of drugs classified as LDR, IDR, and EDR were 0.48 (range 0-1), 0.34 (range 0-1), and 0.18 (range 0-0.80), respectively. The mean numbers of drugs per specimen exhibiting LDR, IDR, and EDR chemoresistance were 2.7, 2.1, and 1.2, respectively. 57 of 70 specimens (81%) had LDR to at least two drugs. 5-FU had the highest frequency of low chemoresistance at 69%, followed by doxorubicin at 67%. Low in vitro resis...Continue Reading

References

Jan 17, 1990·Journal of the National Cancer Institute·D D Von HoffF M Muggia
Aug 1, 1988·American Journal of Clinical Oncology·J FrameR Lippermann
Nov 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C G Moertel
Nov 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P F EngstromH O Douglass
Feb 20, 1999·QJM : Monthly Journal of the Association of Physicians·S Halford, J Waxman
Aug 21, 2001·Breast Cancer Research and Treatment·R S MehtaJ P Fruehauf
Nov 25, 2003·American Journal of Obstetrics and Gynecology·Vera LoizziMichael L Berman
Dec 24, 2003·Acta Oncologica·Isac I SchnirerJaffer A Ajani
Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah SchragUNKNOWN ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays
Aug 27, 2004·Cancer·Matthew H KulkeCharles S Fuchs
Oct 21, 2004·Cancer Investigation·Matthew H KulkeCharles S Fuchs
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Weijing SunUNKNOWN Eastern Cooperative Oncology Group
Jan 24, 2006·The Annals of Thoracic Surgery·Thomas A d'AmatoRicardo J Parker

❮ Previous
Next ❯

Citations

Jan 18, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Wolfgang FiebigerGerhard Hamilton
Feb 26, 2011·Endocrinology and Metabolism Clinics of North America·Saju JosephEugene A Woltering
Jul 24, 2010·The Journal of Thoracic and Cardiovascular Surgery·Aneil A MujoomdarDavid J Sugarbaker
Jan 13, 2019·The Oncologist·Katharine E H ThomasRobert A Ramirez
May 27, 2016·The Oncologist·Robert A RamirezEugene A Woltering
Feb 12, 2014·Molecular Biology Reports·Yong LiDong Wang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.